Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PhaseBio Pharmaceuticals Inc (PHAS)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 | Sep-30-20 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.2 | 0.1 | 0.2 | 0.3 | 10.3 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -98.0% | | | | | -100.0% | -100.0% | -100.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.2 | 0.1 | 0.2 | 0.3 | 10.3 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | |
| Selling, general and administrative [+] | 4.6 | 4.0 | 4.9 | 3.8 | 4.0 | 3.3 | 3.6 | 3.1 |
| General and administrative | 4.6 | 4.0 | 4.9 | 3.8 | 4.0 | 3.3 | 3.6 | 3.1 |
| Research and development | 20.9 | 14.3 | 27.4 | 25.1 | 27.4 | 22.3 | 22.4 | 17.4 |
| EBITDA [+] | -24.7 | -17.6 | -31.5 | -28.4 | -20.5 | -25.2 | -25.6 | -20.4 |
| EBITDA growth | 20.7% | -30.0% | 22.8% | 39.2% | -14.9% | 76.9% | 128.3% | 77.1% |
| EBITDA margin | -11879.3% | -15065.8% | -19924.1% | -8491.3% | -198.0% | | | |
| Depreciation and amortization | 0.6 | 0.6 | 0.6 | 0.1 | 0.6 | 0.5 | 0.3 | 0.1 |
| EBIT [+] | -25.3 | -18.2 | -32.1 | -28.6 | -21.1 | -25.6 | -26.0 | -20.5 |
| EBIT growth | 20.2% | -28.9% | 23.5% | 39.4% | -12.6% | 79.5% | 130.3% | 76.8% |
| EBIT margin | -12169.2% | -15579.5% | -20307.6% | -8530.1% | -203.6% | | | |
| Interest expense, net [+] | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 |
| Interest expense | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 8.7 | 7.2 | -10.8 | -3.1 | -5.8 | -1.4 | -4.1 | -4.3 |
| Gain (loss) on foreign currency transactions | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 |
| Other | 8.6 | 7.1 | -11.0 | -3.3 | -6.0 | -1.7 | -4.4 | -4.7 |
| Pre-tax income | -16.7 | -11.1 | -43.1 | -31.9 | -27.1 | -27.4 | -30.4 | -25.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% |
| Net income | -16.7 | -11.1 | -43.1 | -31.9 | -28.7 | -27.4 | -30.4 | -25.1 |
| Net margin | -8012.0% | -9522.2% | -27284.8% | -9529.6% | -277.4% | | | |
| |
| Basic EPS [+] | ($0.34) | ($0.23) | ($0.98) | ($0.66) | ($0.60) | ($0.87) | ($1.05) | ($0.86) |
| Growth | -43.3% | -73.8% | -6.1% | -22.7% | -38.8% | 68.8% | 153.7% | 116.8% |
| Diluted EPS [+] | ($0.34) | ($0.23) | ($0.98) | ($0.66) | ($0.60) | ($0.87) | ($1.05) | ($0.86) |
| Growth | -43.3% | -73.8% | -6.1% | -22.7% | -38.8% | 68.8% | 153.7% | 116.8% |
| |
| Shares outstanding (basic) [+] | 49.2 | 48.6 | 43.9 | 48.0 | 48.0 | 31.3 | 29.1 | 29.2 |
| Growth | 2.5% | 55.5% | 51.2% | 64.3% | 66.6% | 8.7% | 5.7% | 1.8% |
| Shares outstanding (diluted) [+] | 49.2 | 48.6 | 43.9 | 48.0 | 48.0 | 31.3 | 29.1 | 29.2 |
| Growth | 2.5% | 55.5% | 51.2% | 64.3% | 66.6% | 8.7% | 5.7% | 1.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|